Summary
The assay methods used to determine the concentrations of the newer benzodiazepines include electron-capture gas-liquid chromatography, high performace liquid chromatography with ultraviolet detection, gas chromatography-mass spectrometry, radioassay and radioreceptor assay. The method used frequently is the highly sensitive and specific electron-capture gas-liquid chromatography. Other methods are associated with limitations.
The triazolo- and imidazolebenzodiazepines differ structurally from the ‘classical’ benzodiazepines such as diazepam, and offer distinct differences in pharmacological activity and in time-course of effect. Alprazolam and triazolam, both 1,4-triazolobenzodiazepines, have high affinities for the benzodiazepine receptor as do midazolam and loprazolam, which are 1,4-imidazolebenzodiazepines.
Absorption is characteristically rapid, with peak alprazolam and triazolam concentrations occurring within 1 hour after oral administration. Sublingual administration results in peak alprazolam and triazolam concentrations that are higher and occur earlier than with the oral route.
The volume of distribution of alprazolam and triazolam is approximately 1L. Alprazolam is 70% bound to plasma proteins and the extent of binding is independent of concentration. Similarly, triazolam is approximately 85% bound to plasma proteins, variability in binding being explained by variations in α1-acid glycoprotein concentration.
The 1,4-triazolo ring prevents the oxidative metabolism of the classical benzodiazepines which results in formation of active metabolites with long elimination half-lives. Alprazolam is extensively metabolised: 29 metabolites have been identified in the urine, and its major metabolite, α-hydroxyalprazolam, has pharmacological activity. α-Hydroxyalprazolam and 4-hydroxyalprazolam are detectable in plasma in amounts which account for less than 10% of the administered dose. Mean alprazolam elimination half-life in healthy adult subjects ranges from 9.5 to 12 hours; liver disease prolongs alprazolam elimination, but renal insufficiency does not. Triazolam also undergoes oxidation and subsequent glucuronidation. α-Hydroxytriazolam is the major metabolite, in addition to which 4-hydroxyalprazolam and α-4-hydroxytriazolam have been identified in plasma and urine. The elimination half-life of triazolam ranges between 1.8 and 5.9 hours, while that of the conjugated metabolites is short, approximately 3.8 hours. Accumulation of triazolam or its metabolites after multiple doses does not occur. Liver disease prolongs triazolam elimination from the body, but renal disease does not.
Factors such as age, gender, and obesity can influence the pharmacokinetics of alprazolam and triazolam. The reported drug-drug interactions with both agents are predominantly the result of inhibition of the microsomal enzyme system responsible for the hepatic metabolism and elimination of these benzodiazepines.
Midazolam and loprazolam are basic compounds; the imidazole ring allows for the preparation of aqueous injectable solutions that are stable and well tolerated. Both drugs are rapidly absorbed after oral administration. Peak midazolam concentrations occur in 20 to 60 minutes, while peak loprazolam concentrations are reached in 0.5 to 2 hours. Bioavailability of oral midazolam ranges from 34 to 68%. It is also rapidly absorbed after intramuscular administration, and the bioavailability then ranges from 40 to 100%. The absolute bioavailability of loprazolam in man has not been reported; however, approximately 70 to 75% of the oral dose is absorbed in animals.
The volume of distribution for both midazolam and loprazolam is large, 0.5 to 3 L/kg, with great intersubject variability. The plasma protein binding of midazolam is 95%, while loprazolam is 80% protein bound.
Midazolam undergoes hydroxylation and subsequent glucuronidation. The elimination half-life of midazolam is approximately 2 hours; however, there have been reports of prolonged elimination (> 8 hours) in subpopulations of subjects. The elimination half-life of α-hydroxymidazolam, the major midazolam metabolite, is approximately 1 hour.
Loprazolam is not as rapidly metabolised as midazolam. The major elimination pathway is N-oxidation of the piperazine ring. Depending on the assay method, the elimination half-life for loprazolam has ranged between 4 and 15 hours. The longer half-life may reflect the activity of metabolites, with the actual value being between 4 and 7 hours. The most common type of drug-drug interaction reported for midazolam also involves the inhibition of the microsomal mixed function oxidase system responsible for the metabolism of that drug. Loprazolam interactions have not been extensively studied.
Similar content being viewed by others
References
Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, et al. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 80: 275–278, 1983
Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clinical Pharmacokinetics 9: 177–183, 1984
Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam, and lorazepam. British Journal of Clinical Pharmacology 19: 51–57, 1985
Allen JG, Alderson K, Galloway DB, Hallett C. The effect of midazolam (Hypnovel) administration on antipyrine pharmacokinetics in humans. Xenobiotica 17: 875–879, 1987
Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clinical Pharmacology and Therapeutics 30: 653–661, 1981
Ankier SI, Barclay SP, Warrington SJ. Loprazolam (RV31158)-lack of effect on hepatic microsomal enzyme activity in man. Correspondence. British Journal of Clinical Pharmacology 16: 200–201, 1983
Arendt RM, Greenblatt DJ, Garland WA. Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. Pharmacology 29: 158–164, 1984
Avram MJ, Frazen RJ, Caldwell NJ. Midazolam kinetics in women of two age groups. Clinical Pharmacology and Therapeutics 34: 505–508, 1983
Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 7: 629–638, 1987
Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. Journal of Clinical Pharmacology 28: 240–245, 1988
Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH. Influence of food on midazolam absorption. Journal of Clinical Pharmacology 26: 55–59, 1986
Bornemann LD, Min BH, Crews T, Rees MMC, Blumenthal HP, et al. Dose dependent pharmacokinetics of midazolam. European Journal of Clinical Pharmacology 29: 91–95, 1985
Caldwell CB, Gross JB. Physostigmine reversal of midazolam induced sedation. Anesthesiology 57: 125, 1982
Cartwright PO, Pingel SM. Midazolam and diazepam in ketamine anesthesia. Anesthesia 39: 439–442, 1984
Cho MJ, Scahill TA, Aster JB. Kinetics and equilibrium of the reversible alprazolam ring-opening reaction. Journal of Pharmaceutical Sciences 72: 356–362, 1983
Ciraulo DA, Barnhill JG, Boxenbaum HG, Greenblatt DJ, Smith RB. Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. Journal of Clinical Pharmacology 26: 292–298, 1986
Coassolo Ph, Aubert C, Cano JP. Simultaneous assay of triazolam and its main hydroxy metabolite in plasma and urine by capillary gas chromatography. Journal of Chromatography 274: 161–170, 1983
Cox SR, Kroboth PD, Anderson DH, Smith RB. Mechanism for the interaction between triazolam and cimetidine. Biopharmaceutics and Drug Disposition 7: 567–575, 1986
Crevoisier C, Eckert M, Heizmann P, Thurneysen DJ, Ziegler WH. Relation entre l’effet clinique et la pharmacocinétique du midazolam après administration IV et IM. Arzneimittel-Forschung 31: 2211–2215, 1981
Dehlin O, Bjornson G, Borgesson L, Abrahamsson L, Smith RB. Pharmacokinetics of triazolam in geriatric patients. European Journal of Clinical Pharmacology 25: 91–94, 1983
Dorian P, Sellers CM, Kaplan HL, Hamilton C, Greenblatt DJ, et al. Triazolam and ethanol interaction: kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics 37: 558–562, 1985
Dundee JW, Collier PS, Carlisle RJT, Harper KW. Prolonged midazolam elimination half-life. British Journal of Clinical Pharmacology 21: 425–429, 1986a
Dundee JW, Halliday WJ, McMurray TJ. Aspirin and probenecid pretreatment influences the potency of thiopentone and the onset of action of midazolam. European Journal of Anesthesiology 3: 247–251, 1986b
Eberts FS, Pilopoulos Y, Reineke LM, Vliek RW. Disposition of 14C-alprazolam, a new anxiolytic-antidepressant in man. Abstract. Pharmacologist 22: 279, 1980
Eberts FS, Pilopoulos Y, Reineke LM, Vliek RW. Triazolam disposition. Clinical Pharmacology and Therapeutics 29: 81–93, 1981
Ellinwood EH, Heatherly DG, Nikardo AM, Bjornsson TD, Kilts C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 86: 392–399, 1985
Elliott P, Dundee JW, Elwood RJ, Collier PS. The influence of H2 receptor antagonists on the plasma concentrations of midazolam and temazepam. European Journal of Anesthesiology 1: 245–251, 1984
Elwood RJ, Hildebrande PJ, Dundee JW, Collier PS. Ranitidine influences the uptake of oral midazolam. British Journal of Clinical Pharmacology 15: 743–745, 1983
Fee JP, Collier PS, Howard PJ, Dundee JW. Cimetidine and ranitidine increase midazolam bioavailability. Clinical Pharmacology and Therapeutics 41: 80–84, 1987
Ford S, Ankier SI, Corless D, Bevan CD, Pidgen AW, et al. Pharmacokinetics of loprazolam and its principal metabolite in young subjects and elderly hospital patients. Xenobiotica 8: 1001–1009, 1987
Friedman H, Greenblatt DJ, Burstein ES, Harvatz JS, Shader RI. Population study of triazolam pharmacokinetics. British Journal of Clinical Pharmacology 22: 639–642, 1986
Garzone PD. Stable isotope technology in drug-drug interactions: the effects of cimetidine, ranitidine, and antacid on the pharmacokinetics of midazolam, Ph.D dissertation, University of Pittsburgh, 1987
Gerecke M. Chemical structure and properties of midazolam compared with other benzodiazepines. British Journal of Clinical Pharmacology 16: 11S–16S, 1983
Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, et al. Effect of age, gender and obesity on midazolam’s kinetics. Anesthesiology 61: 27–35, 1984
Greenblatt DJ, Arendt RM, Abernethy DR, Giles HG, Sellers EM, et al. In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. British Journal of Anaesthesiology 55: 985–989, 1983c
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, et al. Alprazolam kinetics in the elderly: relation to anti-pyrine disposition. Archives of General Psychiatry 40: 287–290, 1983a
Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, et al. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. British Journal of Clinical Pharmacology 15: 303–309, 1983b
Greenblatt DJ, Divoll M, Moschitto LJ, Shader RI. Electron-capture gas Chromatographic analysis of the triazolobenzodiazepines alprazolam and triazolam. Journal of Chromatography 225: 202–207, 1981a
Greenblatt DJ, Locniskar A, Ochs HR, Lauven PM. Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology 55: 176–179, 1981b
Greenblatt DJ, Locniskar A, Scavone JM, Blyden GJ, Ochs HR, et al. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesthesia and Analgesia 65: 176–180, 1986
Handel J, Ziegler G, Gemeinhardt A, Stuber H, Fischer C, et al. Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. British Journal of Clinical Pharmacology 25: 243–250, 1988
Harper KW, Collier PS, Dundee JW, Elliot P, Halliday NJ, et al. Age and nature of operation influence the pharmacokinetics of midazolam. British Journal of Anaesthesiology 57: 866–871, 1985
Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 16: 43S–49S, 1983
Heizmann P, Ziegler WH. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittel-Forschung 31: 2220–2222, 1981
Hengen N, Hoffman E, Schick C. Liquid Chromatographic assay of the new benzodiazepine derivative GP 55129 in plasma and urine after application to humans. Naunyn-Schmiedeberg’s Archives of Pharmacology 319 (Suppl.): R88, 1982
Illing HPA, Bevan CD, Robinson JD, Chamberlain J, Fromson JM. Metabolism of loprazolam in rat, dog and man in vivo. Xenobiotica 13: 539–553, 1983b
Illing HPA, Ings RMJ, Johnson KI, Fromson JM. Disposition of 14C-loprazolam in animals and man. Xenobiotica 13: 439–449, 1983a
Jochemsen R, Van Rijn PA, Hazelzet TGM, Van Boxtel CJ, Breimer DD. Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration. Bio-pharmaceutics and Drug Disposition 7: 53–61, 1986
Jochemsen R, Wesselman JGJ, Van Boxtel CJ, Hermans J, Breimer DD. Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. British Journal of Clinical Pharmacology 16 (Suppl. 2): 291S–298S, 1983
Juhl RP, Van Thiel DH, Dittert LW, Smith RB. Alprazolam pharmacokinetics in alcoholic liver disease. Journal of Clinical Pharmacology 24: 113–119, 1984
Kanto J, Djovall S, Erkkola R, Hiberg J, Kangas L. Placental transfer and maternal midazolam kinetics. Clinical Pharmacology and Therapeutics 33: 786–791, 1983
Kanto J, Himberg JJ, Heikkila H, Arola M, Jalonen J, et al. Midazolam kinetics before, during and after cardiopulmonary bypass surgery. International Journal of Clinical Pharmacy Research 2: 123–126, 1985
Kesson CM, Gray JMD, Lawson DH. A pilot study into the secretion of loprazolam in human breast milk. In Loprazolam clinical workshop, p. 31, Medicine Publishing Foundation, Oxford, 1983
Kitagawa H, Esumi Y, Krurosawa S, Sekine S, Yokoshima T. Metabolism of 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo [4,3a] [1,4] benzodiazepine, triazolam, a new central depressant, I: absorption, distribution and excretion in rats, dogs, and monkeys. Xenobiotica 9: 415–428, 1979
Klotz U, Arvela P, Rosenkranz B. Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam. Clinical Pharmacology and Therapeutics 38: 652–655, 1985
Klotz U, Mikus G, Zekorn C, Eichelbaum M. Pharmacokinetics of midazolam in relation to polymorphic sparteine oxidation. British Journal of Clinical Pharmacology 22: 618–620, 1986
Klotz U, Reimann IW. Chronopharmacokinetic study with prolonged infusion of midazolam. Clinical Pharmacokinetics 9: 469–474, 1984
Klotz U, Ziegler G. Physiologic and temporal variation in hepatic elimination of midazolam. Clinical Pharmacology and Therapeutics 32: 107–112, 1982
Konishi M, Hirai K, Mori Y. Kinetics and mechanisms of the equilibrium reaction of triazolam in aqueous solution. Journal of Pharmaceutical Sciences 71: 1328–1334, 1982
Krieger J, Perianu M, Bertagna C, Mangen P, Kurtz D. Hypnotic benzodiazepines: relationship between sleep parameters and pharmacokinetics of loprazolam. Drug Development and Research 3: 143–152, 1983
Kroboth PD, Smith RB, Rosanske T, Hamilton JM, McAuley JW, et al. Triazolam route of administration studies, I: pharmacokinetics. Abstract. Pharmaceutical Research 3(S): 111, 1986
Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, et al. Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics. British Journal of Clinical Pharmacology 19: 839–842, 1985
Kroboth PD, Smith RB, Sorkin MI, Silver M, Rault R, et al. Triazolam protein binding correlation with alpha-1 acid glycoprotein concentration. Clinical Pharmacology and Therapeutics 36: 379–383, 1984
Kroboth PD, Smith RB, Van Thiel DH, Juhl RP. Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. Journal of Clinical Pharmacology 27: 555–560, 1987
Levasseur FA, Caille G, Elie R, Vezina M, Lariviere L. Electron-capture gas Chromatographic determination of loprazolam in plasma and a pharmacokinetic application. Biopharmaceutics and Drug Disposition 6: 381–387, 1985
Macgilchrist AJ, Birnie GG, Cook A, Scohie G, Murray T, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 27: 190–195, 1987
McAuley JW, Hamilton JM, Kroboth PD, Smith RB. Alprazolam in elderly: kinetics and dynamics during multiple dosing. Abstract. Pharmaceutical Research 4(S): 99, 1987
McInnes GT, Banting EA, Ings RMJ, Robinson J, Ankier SI. Pharmacokinetics and pharmacodynamics following single and repeated nightly administration of loprazolam, a new benzodiazepine hypnotic. British Journal of Clinical Pharmacology 19: 649–656, 1985
McManus IC. The interaction of loprazolam and alcohol in a volunteer study. In Loprazolam clinical workshop, p. 30, Medicine Publishing Foundation, Oxford, 1983
Mendelson WB, Skolnick P, Martin JV, Luu MD, Wagner R, et al. Diazepam-stimulated increase in the synaptosomal uptake of 45Ca++: reversal by dihydropyridine calcium channel antagonists. European Journal of Pharmacology 104: 181–183, 1984
Muakkassah SF, Bidlack WR, Lang WCT. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochemistry and Pharmacology 30: 1651–1658, 1981
Moschitto LJ, Greenblatt DJ. Concentration-independent plasma protein binding of benzodiazepines. Journal of Pharmacy and Pharmacology 35: 179–180, 1983
Ochs HR, Greenblatt DJ, Arendt RM, Hubbel W, Shader RI. Pharmacokinetic non-interaction of triazolam and ethanol. Journal of Clinical Psychopharmacology 4: 106–107, 1984b
Ochs HR, Greenblatt DJ, Burstein ES. Lack of influence of cigarette smoking on triazolam’s pharmacokinetics. British Journal of Clinical Pharmacology 23: 759–763, 1987
Ochs HR, Greenblatt DJ, Knuchel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. British Journal of Clinical Pharmacology 16: 743–746, 1983
Ochs HR, Greenblatt DJ, Knuchel M. Kinetics of diazepam, midazolam and lorazepam in cigarette smokers. Chest 87: 223–226, 1985
Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. Alprazolam kinetics in patients with renal insufficiency. Journal of Clinical Psychopharmacology 6: 292–294, 1986
Ochs HR, Greenblatt DJ, Verburg-Ochs B. Propranolol interaction with diazepam, lorazepam and alprazolam. Clinical Pharmacology and Therapeutics 36: 451–455, 1984a
Persson P, Nilsson A, Hartvey P, Tamsen A. Pharmacokinetics of midazolam in total IV anaesthesia. British Journal of Anaesthesiology 59: 548–556, 1987
Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and humans. International Journal of Clinical Pharmacology Research 111: 449–458, 1983
Phillips JP, Antale EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. Journal of Clinical Psychopharmacology 6: 297–299, 1986
Philopoulos Y, Eberts FS, Vliek RW, Russell RR, Collin RJ. Metabolism of alprazolam. Enzyme induction study with rat hepatic microsomal mixed function oxidase. Upjohn Technical Report, 1980
Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam in healthy subjects. International Journal of Clinical Pharmacology, Therapy and Toxicology 23: 447–451, 1985
Puglisi CV, Meyer JC, D’Arconte L, Brooks MA, deSilva JAF. Determination of water soluble imidazo-l,4-benzodiazepines in blood by electron-capture gas liquid chromatography and in urine by differential pulse polarography. Journal of Chromatography 14: 81–96, 1978
Reineke LM, Vliek RW, Eberts FS. Metabolism of alprazolam. Urine metabolite profile in human, dog and rat. Upjohn Technical Report, 1978
Rinetti M, Ascalone V, Colombi Zinelli L, Cisternino M. A pharmacokinetic study on midazolam in compensated liver cirrhosis. International Journal of Clinical Pharmacy Research 6: 405–411, 1985
Rubio F, Miwa BJ, Garland WA. Determination of midazolam and two metabolites of midazolam in human plasma by gas chromatography-negative chemical-ionization mass spectrometry. Journal of Chromatography 233: 157–165, 1982
Saint Maurice C, Meistelman C, Rey E, Esteve C, DeLauture D, et al. The pharmacokinetics of rectal midazolam for premedication in children. Anesthesiology 65: 536–538, 1986
Salonen M, Aantau E, Aaltonen L, Kanto J. Importance of the interaction of midazolam and cimetidine. Acta Pharmacologica et Toxicologica 58: 91–95, 1986
Scavone JM, Greenblatt DJ, Friedman H, Shader RI. Enhanced bioavailability of triazolam following sublingual versus oral administration. Clinical Pharmacology 26: 208–210, 1986
Scavone JM, Greenblatt DJ, Shader RI. Alprazolam kinetics following sublingual and oral administration. Journal of Clinical Psychopharmacology 7: 332–334, 1987
Servin F, Enriquez I, Fournet M, Failler JM, Favinotti R, et al. Pharmacokinetics of midazolam used as an intravenous induction agent for patients over 80 years of age. European Journal of Anesthesiology 4: 1–7, 1987
Sethy VH, Harris DW. Determination of biological activity of alprazolam, triazolam and their metabolites. Journal of Pharmacy and Pharmacology 34: 115–116, 1982
Sjövall S, Kanto J, Himberg JT, Hovi-Viander M, Salo M. CSF penetration and pharmacokinetics of midazolam. European Journal of Clinical Pharmacology 25: 247–251, 1983
Smith MT, Eadie MJ, O’Rourke Brophy T. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 19: 271–278, 1981
Smith MT, Heazlewood V, Eadie MJ, O’Rourke Brophy T, Tyrer JH. Pharmacokinetics of midazolam in the aged. European Journal of Clinical Pharmacology 26: 381–388, 1984a
Smith RB, Divoll M, Gillespie WR, Greenblatt DJ. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. Journal of Clinical Psychopharmacology 3: 172–176, 1983a
Smith RB, Gwilt PR, Wright CE. Single and multiple dose pharmacokinetics of oral alaprazolam in healthy smoking and nonsmoking men. Clinical Pharmacy 2: 139–143, 1983b
Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentration and tolerance to sedative and psychomotor effects. Psychopharmacology 93: 105–112, 1987
Smith RB, Kroboth PD, Phillips JP. Temporal variation in triazolam pharmacokinetics and pharmacodynamics after oral administration. Journal of Clinical Pharmacology 26: 120–124, 1986
Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 84: 452–456, 1984b
Smith RB, Schoenfeld MJ. Effect of food on the bioavailability of Xanax (alprazolam) following a single oral 1.0mg dose. Upjohn Technical Report, 1981a
Smith RB, Schoenfeld MJ. The effect of food on the bioavailability of 0.5mg Halcion administered as a single dose. Upjohn Technical Report, 1981b
Stevens LA, Bevan CD, Salmon J, Krieger J, Perianu M, et al. Single and repeated dose kinetics of the hypnotic agent loprazolam in healthy volunteers. European Journal of Clinical Pharmacology 25: 651–655, 1983
Stevens LA, Pidgen AW, Bevan CD, Ings RMJ, Lawrence JR, et al. Correlation of the clinical pharmacodynamics of loprazolam with serum concentrations. Xenobiotica 15: 623–631, 1985
Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam and lorazepam kinetics. Clinical Pharmacology and Therapeutics 36: 683–690, 1984
Suhhan Z, Hindmarch I. The effects of midazolam in conjunction with alcohol on iconic memory and free recall. Neuropsychobiology 9: 230–234, 1983
Swift CG, Swift MR, Ankier SI, Pidgen A, Robinson J. Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly. British Journal of Clinical Pharmacology 20: 119–128, 1985
Thomas RC, Judy RW. Tissue levels of alprazolam-14C(U-31889) in the mouse as determined by whole body section autoradiography. Upjohn Company, 1976
Tuzel IH, Skinner JM, Wyler-Plaut R. Injectable midazolam. Investigational drug brochure. Hoffmann-LaRoche Inc., 1984
Vasiliades J, Sahawneh TH. Determination of midazolam by high performance liquid chromatography. Journal of Chromatography 225: 266–271, 1981
Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 59: 390–394, 1983
Vree TB, Baars AM, Booij LHD, Driessen JJ. Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography, Arzneimittel-Forschung 31: 2215–2219, 1981
White SM, Allen JG, Altman JFB. The effects of midazolam administration on the pharmacokinetics of antipyrine in the rat. Xenobiotica 17: 869–873, 1987
Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. British Journal of Clinical Pharmacology 16: 63–69, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garzone, P.D., Kroboth, P.D. Pharmacokinetics of the Newer Benzodiazepines. Clin-Pharmacokinet 16, 337–364 (1989). https://doi.org/10.2165/00003088-198916060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198916060-00002